Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Samsung Biologics (207940 KS): Momentum Accelerates in 3Q; Solid Order Book; Reaffirms FY Guidance

Samsung Biologics (207940 KS): Starts 2026 with Double-Digit Revenue Growth; FY Guidance Reaffirmed

Samsung Biologics (207940 KS): 2025 Revenue Meet Guidance; Big Fat Order Book Lends Visibility Ahead

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/samsung-biologics-co-ltd" target="_blank" data-smartkarma-citation="entities:22932:1" rel="noopener">Samsung Biologics (207940 KS)</a> reported 2Q26 revenue and operating profit of KRW1.3T (+30% YoY) and KRW586B (+23% YoY), driven by stable operations across Plants 1–4 and favorable Fx.</li>
<li>The company is on track to meet the upper end of FY guidance range, driven by stable operation of Rockville facility, progressive ramp-up of Plant 5, and favorable Fx.</li>
<li>Samsung Biologics announced all-cash public tender offer to acquire PolyPeptide, a leading global CDMO specializing in peptide-based API, for CHF1.5B. The transaction is expected to be completed this year.</li>
</ul>



Samsung Biologics (207940 KS) reported 2Q26 revenue and operating profit of KRW1.3T (+30% YoY) and KRW586B (+23% YoY), driven by stable operations across Plants 1–4 and favorable Fx.
The company is on track to meet the upper end of FY guidance range, driven by stable operation of Rockville facility, progressive ramp-up of Plant 5, and favorable Fx.
Samsung Biologics announced all-cash public tender offer to acquire PolyPeptide, a leading global CDMO specializing in peptide-based API, for CHF1.5B. The transaction is expected to be completed this year.


Samsung Biologics (207940 KS): Robust 2Q Result; New Acquisition to Expand Modality into Peptides